ArticleStem cell research & therapy2019
The therapeutic potential of induced hepatocyte-like cells generated by direct reprogramming on hepatic fibrosis.
Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Hepatocyte-like cell therapy for end-stage liver disease: From basic science to clinical application.Liver research (Beijing, China) · 2026Review
- Induced hepatocyte-like cells derived from adipose-derived stem cells alleviates liver injury in mice infected with Echinococcus Multilocularis.Scientific reports · 2024Article
- Chemical approaches targeting the hurdles of hepatocyte transplantation: mechanisms, applications, and advances.Frontiers in cell and developmental biology · 2024Review
- Stem cell therapy for hepatocellular carcinoma and end-stage liver disease.Journal of the Egyptian National Cancer Institute · 2023Review
- Trehalose prevents glyphosate-induced hepatic steatosis in roosters by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation.Veterinary research communications · 2023Article
- Therapeutic interventions of acute and chronic liver disorders: A comprehensive review.World journal of hepatology · 2023Review
- Orchestrated regulation of immune inflammation with cell therapy in pediatric acute liver injury.Frontiers in immunology · 2023Review
- Limitations and challenges of direct cell reprogramming in vitro and in vivo.Histology and histopathology · 2022Review
- Liver Regeneration and Cell Transplantation for End-Stage Liver Disease.Biomolecules · 2021Review
- Induction and Maturation of Hepatocyte-Like CellsFrontiers in cell and developmental biology · 2021Review
- Current and Emerging Approaches for Hepatic Fibrosis Treatment.Gastroenterology research and practice · 2021Review
- The Application of Induced Pluripotent Stem Cells Against Liver Diseases: An Update and a Review.Frontiers in medicine · 2021Review
- Phenotype instability of hepatocyte-like cells produced by direct reprogramming of mesenchymal stromal cells.Stem cell research & therapy · 2020Article
- Direct cell-fate conversion of somatic cells: Toward regenerative medicine and industries.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUntil now, there is no effective anti-fibrotic therapy available for liver cirrhosis. Stem cell therapies have been studied for the treatment of hepatic fibrosis. However, the use of embryonic stem cells or induced pluripotent stem cells (iPSC) has limitations such as ethical concern or malignancy potential. Induced hepatocyte-like cells (iHEPs) generated by direct reprogramming technology may overcome these limitations.
methodsIn this study, we generated iHEPs by direct reprogramming from mouse embryonic fibroblast (MEF) either using specific transcription factors such as c-Myc and Klf-4 (type A), or adding small molecules to HNF1α (type B).
resultsWe investigated the effect of iHEPs on acute liver injury and chronic hepatic fibrosis animal models induced by CCl
conclusionsOur study suggests that iHEPs may be used as a novel therapeutic strategy for the treatment of hepatic fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.